Study identifier:D7130C00001
ClinicalTrials.gov identifier:NCT06115967
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy participants
Rheumatoid Arthritis
Phase 1
Yes
AZD6912, Placebo
All
64
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD6912 Dose 1 Participants will receive AZD6912 Dose 1. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 Dose 2 Participants will receive AZD6912 Dose 2. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 Dose 3 Participants will receive AZD6912 Dose 3. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 Dose 4 Participants will receive AZD6912 Dose 4. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 Dose 5 Participants will receive AZD6912 Dose 5. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 Dose 6 Participants will receive AZD6912 Dose 6. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Placebo Comparator: Placebo Participants will receive Placebo. | Drug: Placebo Placebo will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 additional Japanese cohort 1 Participants will receive AZD6912. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |
Experimental: AZD6912 additional Japanese cohort 2 Participants will receive AZD6912. | Drug: AZD6912 AZD6912 will be administered as a single sub-cutaneous dose. |